REGENERX BIOPHARMACEUTICALS INC
REGENERX BIOPHARMACEUTICALS INC (RGRX): 3 pipeline candidates · ~2 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
1.7 months
D/E -1.05 · 0% dilution
Lead: Phase 3
3 candidates
N/A
N/A
A transparent, data-derived signal for REGENERX BIOPHARMACEUTICALS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$898
Cash
$102K
Quarterly Burn
$189K
Runway
1.7 mo
Revenue
$19K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Frequently asked questions
How many drug candidates are in REGENERX BIOPHARMACEUTICALS INC's pipeline?
REGENERX BIOPHARMACEUTICALS INC (RGRX) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is REGENERX BIOPHARMACEUTICALS INC's lead drug candidate?
REGENERX BIOPHARMACEUTICALS INC's most advanced tracked candidate is rgn-137 (Phase 3) for Dermal wounds, reduction of scar tissue, and epidermolysis bullosa.
What is REGENERX BIOPHARMACEUTICALS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, REGENERX BIOPHARMACEUTICALS INC has approximately 1.7 months of cash runway.
What is REGENERX BIOPHARMACEUTICALS INC's market capitalization?
REGENERX BIOPHARMACEUTICALS INC's market capitalization is approximately $898.
Who is the CEO of REGENERX BIOPHARMACEUTICALS INC?
Mr. J. J. Finkelstein is the chief executive officer of REGENERX BIOPHARMACEUTICALS INC (RGRX).
Get the full picture on REGENERX BIOPHARMACEUTICALS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.